Related references
Note: Only part of the references are listed.Parasitic pharmacology: A plausible mechanism of action for cannabidiol
Geert Jan Groeneveld et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2020)
CLINICAL UPDATE Medicinal use of cannabis based products and cannabinoids
Tom P. Freeman et al.
BMJ-BRITISH MEDICAL JOURNAL (2019)
Cannabidiol Adverse Effects and Toxicity
Marilyn A. Huestis et al.
CURRENT NEUROPHARMACOLOGY (2019)
European drug agency approves cannabis-based medicine for severe forms of epilepsy
Jacqui Wise
BMJ-BRITISH MEDICAL JOURNAL (2019)
The unexpected identification of the cannabimimetic, 5F-ADB, and dextromethorphan in commercially available cannabidiol e-liquids
Justin L. Poklis et al.
FORENSIC SCIENCE INTERNATIONAL (2019)
Benzodiazepines or related drugs and risk of pneumonia: A systematic review and meta-analysis
Guo-qing Sun et al.
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY (2019)
A Phase 1, Open-Label, Pharmacokinetic Trial to Investigate Possible Drug-Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects
Gilmour Morrison et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2019)
Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial
Philip McGuire et al.
AMERICAN JOURNAL OF PSYCHIATRY (2018)
Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial
Elizabeth A. Thiele et al.
LANCET (2018)
Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome
Orrin Devinsky et al.
NEUROLOGY (2018)
Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome
Orrin Devinsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial
Douglas L. Boggs et al.
PSYCHOPHARMACOLOGY (2018)
Dronabinol oral solution in the management of anorexia and weight loss in AIDS and cancer
Melissa E. Badowski et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2018)
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects
Lesley Taylor et al.
CNS DRUGS (2018)
Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis
Simona Lattanzi et al.
DRUGS (2018)
Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial
Kerri A. Schoedel et al.
EPILEPSY & BEHAVIOR (2018)
Labeling Accuracy of Cannabidiol Extracts Sold Online
Marcel O. Bonn-Miller et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Endocannabinoid modulation of homeostatic and non-homeostatic feeding circuits
Benjamin K. Lau et al.
NEUROPHARMACOLOGY (2017)
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome
Orrin Devinsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Low-Dose Cannabidiol Is Safe but Not Effective in the Treatment for Crohn's Disease, a Randomized Controlled Trial
Timna Naftali et al.
DIGESTIVE DISEASES AND SCIENCES (2017)
An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies
Kerstin Iffland et al.
CANNABIS AND CANNABINOID RESEARCH (2017)
Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study
Khalid A. Jadoon et al.
DIABETES CARE (2016)
Cannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence
Cathrin Rohleder et al.
FRONTIERS IN PHARMACOLOGY (2016)
Are cannabidiol and Δ9-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review
John M. McPartland et al.
BRITISH JOURNAL OF PHARMACOLOGY (2015)
Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor
R. B. Laprairie et al.
BRITISH JOURNAL OF PHARMACOLOGY (2015)
Cannabinoids for Medical Use A Systematic Review and Meta-analysis
Penny F. Whiting et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Dronabinol in Severe, Enduring Anorexia Nervosa: A Randomized Controlled Trial
Alin Andries et al.
INTERNATIONAL JOURNAL OF EATING DISORDERS (2014)
Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders
Alline Cristina Campos et al.
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES (2012)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Cannabidiol Attenuates the Appetitive Effects of Δ9-Tetrahydrocannabinol in Humans Smoking Their Chosen Cannabis
Celia J. A. Morgan et al.
NEUROPSYCHOPHARMACOLOGY (2010)
The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Delta(9)-tetrahydrocannabinol, cannabidiol and Delta(9)-tetrahydrocannabivarin
R. G. Pertwee
BRITISH JOURNAL OF PHARMACOLOGY (2008)
5-lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid
P. Massi et al.
JOURNAL OF NEUROCHEMISTRY (2008)
Cannabinoids and the gastrointestinal tract
RG Pertwee
GUT (2001)
Share Paper
